- Report
- August 2024
- 175 Pages
Global
From €4722EUR$5,000USD£4,016GBP
- Report
- March 2025
- 200 Pages
Global
From €4240EUR$4,490USD£3,607GBP
- Report
- May 2024
- 140 Pages
Global
From €6138EUR$6,499USD£5,220GBP
- Report
- October 2022
- 138 Pages
Global
From €4203EUR$4,450USD£3,575GBP
- Report
- August 2023
- 145 Pages
Global
From €2975EUR$3,150USD£2,530GBP
- Report
- July 2024
- 70 Pages
Brazil
From €4486EUR$4,750USD£3,815GBP
- Report
- February 2024
- 70 Pages
South Africa
From €4486EUR$4,750USD£3,815GBP
- Report
- February 2024
- 70 Pages
Indonesia
From €4486EUR$4,750USD£3,815GBP
- Report
- February 2024
- 70 Pages
Philippines
From €4486EUR$4,750USD£3,815GBP
- Report
- February 2024
- 70 Pages
India
From €4486EUR$4,750USD£3,815GBP
- Report
- February 2024
- 150 Pages
Global
From €4486EUR$4,750USD£3,815GBP
- Report
- February 2024
- 70 Pages
Japan
From €4486EUR$4,750USD£3,815GBP
- Report
- February 2024
- 70 Pages
Italy
From €4486EUR$4,750USD£3,815GBP
- Report
- February 2024
- 70 Pages
India
From €4486EUR$4,750USD£3,815GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4486EUR$4,750USD£3,815GBP
- Report
- February 2024
- 70 Pages
North America
From €4486EUR$4,750USD£3,815GBP
- Report
- February 2024
- 70 Pages
Europe
From €4486EUR$4,750USD£3,815GBP
- Report
- February 2024
- 70 Pages
Asia Pacific
From €4486EUR$4,750USD£3,815GBP
- Report
- February 2024
- 70 Pages
Latin America
From €4486EUR$4,750USD£3,815GBP
- Report
- February 2024
- 70 Pages
Germany
From €4486EUR$4,750USD£3,815GBP

Linagliptin is a drug used to treat type 2 diabetes, a condition in which the body does not produce enough insulin or does not use insulin properly. It belongs to a class of drugs known as dipeptidyl peptidase-4 (DPP-4) inhibitors, which work by increasing the amount of insulin released by the pancreas. Linagliptin is used in combination with diet and exercise to improve glycemic control in adults with type 2 diabetes. It is also used to reduce the risk of cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
Linagliptin is part of the Endocrine and Metabolic Disorders Drugs market, which includes drugs used to treat conditions such as diabetes, obesity, and thyroid disorders. These drugs are used to control blood sugar levels, reduce cholesterol, and regulate hormones.
Companies in the Linagliptin market include Boehringer Ingelheim, Merck, Novartis, and Eli Lilly. Show Less Read more